Physician profile
Takkin Lo
NPI 1942221742
$324,215.42
in general payments reported to CMS, 2019-2025
26 companies · $37K in 2025
The $37K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $18K · 2021: $18K · 2022: $19K · 2023: $136K · 2024: $74K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $199K · Travel and Lodging: $33K · Food and Beverage: $9,530 · Consulting Fee: $4,120 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $199,070.00 |
| Travel and Lodging | $33,479.73 |
| Food and Beverage | $9,530.20 |
| Consulting Fee | $4,120.00 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $205,257.74 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $54,512.00 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48,121.88 | 2019-2025 | Ofev |
| Insmed, INC. | $13,708.28 | 2019-2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $642.35 | 2019-2022 | |
| Genzyme Corporation | $279.69 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $271.02 | 2019-2024 | Dupixent |
| Medline Industries Lp | $218.36 | 2019-2022 | |
| Philips North America LLC | $168.20 | 2022-2025 | Encore, (8874) Incourage |
| Abbvie INC. | $163.78 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.89 | 2021-2023 | Lifevest |
| Pharming Healthcare, INC. | $119.37 | 2024 | Joenja |
| Intercept Pharmaceuticals, INC. | $110.48 | 2022-2024 | Ocaliva |
| Sanofi-Aventis U.S. LLC | $88.99 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $71.89 | 2020-2024 | Opdivo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $54.50 | 2019 | |
| Pfizer INC. | $47.94 | 2019-2022 | |
| Allergan, INC. | $44.21 | 2019 | |
| Dova Pharmaceuticals | $43.18 | 2021 | |
| Mirum Pharmaceuticals, INC. | $26.89 | 2024 | Livmarli |
| Irhythm Technologies, INC. | $24.65 | 2022 | |
| Mallinckrodt Hospital Products INC. | $21.45 | 2023 | Terlivaz |
| Orphalan INC | $21.01 | 2024 | Cuvrior |
| Merck Sharp & Dohme LLC | $19.98 | 2024 | Winrevair |
| Esperion Therapeutics, INC. | $17.47 | 2020 | |
| Dynavax Technologies Corporation | $11.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Takkin Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.